Tailor Made Compounding LLC - 594743 - 04/01/2020

Regulatory 90/100Rated 90/100Source typeRegulator or clinical registryIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology →
April 1, 2020↗ source

FDA warned Tailor Made Compounding LLC (Nicholasville, KY) after a 2018 inspection found it compounded drug products with bulk substances ineligible for 503A exemptions. The letter explicitly lists the compounded substances: Follistatin, GHRP-2, GHRP-6, AOD 9604, BPC 157, Bremelanotide (PT-141), Cerebrolysin, DSIP, Epitalon, GHK-Cu, Ipamorelin, LL-37, Melanotan II, Selank, Semax, and CJC 1295, among others. The firm was cited for insanitary aseptic processing (adulteration), unapproved new drugs, and misbranding, and removed GHRP-2 and GHRP-6 from its formulary in response.

Related peptides

BPC-157GHK-CuIpamorelinCJC-1295Melanotan IIBremelanotideGHRP-2GHRP-6AOD-9604EpitalonLL-37SelankSemaxFollistatinCerebrolysinDSIP
We summarize, we don't invent — every detail here traces to a real, linked source, and the badge reflects how trustworthy that source is. Read the original and decide for yourself.

Free: The Peptide Stack Cheat-Sheet

The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.

No spam. Unsubscribe anytime.